scholarly journals ADAMTS8 Expression is a Potential Prognostic Biomarker for Postoperative Metastasis in Lymph Node-Negative Early-Stage Invasive Breast Carcinoma Patients

2021 ◽  
Vol Volume 14 ◽  
pp. 1701-1713
Author(s):  
Yao Li ◽  
Xin Yang ◽  
Jie Sun ◽  
Yangyang Zhao ◽  
Qi Zhou ◽  
...  
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Prognostic Biomarker ◽  
Early Stage ◽  
Invasive Breast Carcinoma ◽  
Node Negative

scholarly journals Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery

Cancer ◽  
2005 ◽  
Vol 104 (2) ◽  
pp. 240-250 ◽  
Author(s):  
Mohamed Benchalal ◽  
Elisabeth Le Prisé ◽  
Brigitte de Lafontan ◽  
Dominique Berton-Rigaud ◽  
Yazid Belkacemi ◽  
...  
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Local Recurrence ◽  
Early Stage ◽  
Breast Conserving Surgery ◽  
Invasive Breast Carcinoma ◽  
Node Positive ◽  
Lymph Node Positive

Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma

2006 ◽  
Vol 42 (3) ◽  
pp. 357-362 ◽  
Author(s):  
A.H.S. Lee ◽  
S.E. Pinder ◽  
R.D. Macmillan ◽  
M. Mitchell ◽  
I.O. Ellis ◽  
...  
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Prognostic Value ◽  
Lymphovascular Invasion ◽  
Invasive Breast Carcinoma ◽  
Node Negative

scholarly journals Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0)

Cancer ◽  
1997 ◽  
Vol 79 (4) ◽  
pp. 761-771 ◽  
Author(s):  
Arthur K.�C. Lee ◽  
Massimo Loda ◽  
Gasan Mackarem ◽  
Silvano Bosari ◽  
Ronald A. DeLellis ◽  
...  
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Invasive Breast Carcinoma ◽  
Node Negative

MCM4 as a prognostic biomarker of early-stage lung cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21033-e21033
Author(s):  
Virote Sriuranpong ◽  
Sutima Luangdilok ◽  
Poonchavist Chantranuwatana ◽  
Nussara Leeladejkul ◽  
Nopporn Pornpatanarak ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymphovascular Invasion ◽  
Prognostic Biomarker ◽  
Early Stage ◽  
Lymph Node Involvement ◽  
Early Stage Lung Cancer ◽  
Node Negative ◽  
Node Involvement ◽  
Stage Lung Cancer

e21033 Background: Prognostic biomarker in early-stage lung cancer is less well defined. Despite early detection, one-third of patients with completely resected early-stage lung cancer without lymph node involvement have a recurrence. Our main objective is to investigate potential biomarkers useful in classification and predicting prognosis of this early-stage lung cancer, particularly in lymph node-negative subgroup. Methods: In discovery phase, we performed proteomic profiling on 60 lung cancer tissues to distinguish solid versus non-solid adenocarcinoma. Relative protein quantification was analyzed using Tandem Mass Tag mass spectrometry. In validation phase, tumor tissues from an additional cohort were analyzed by immunohistochemistry in conjunction with quantitative image analysis to confirm the differential expression of significantly altered proteins, including MCM2, MCM4, MCM6, SCAMP3, DPP4 and MYH11. Prognostic potentials of each biomarker were analyzed with univariate and multivariate analyses. Results: Quantitative proteomic analysis of predominantly solid versus non-solid adenocarcinoma tissues showed 30 differentially expressed proteins consisting of 13 increased and 17 decreased proteins found in solid compared with non-solid adenocarcinoma. Four most increased proteins (MCM2, MCM4, MCM6, and SCAMP3) and two most decreased proteins (DPP4 and MYH11) were selected for immunostaining in the validation cohort of 204 patients with resected adenocarcinoma without lymph node involvement. 57 out of 204 (27.9%) patients had recurrent disease. The high expression level of MCM4 was the strongest signature for disease recurrence (HR 4.85, 95%CI 2.78-8.47, p < 0.0001) and remained significant under multivariate analyses adjusted for TNM stage, histologic subtypes, lymphovascular invasion, tumor necrosis, and adjuvant chemotherapy. Recurrence-free survival (RFS) was significantly shorter in patients with high MCM4 compared with low MCM4 (5-y RFS 50% vs 84%, p < 0.0001) and remained highly significant within stage IA (5-y RFS 69% vs 93%, p < 0.0001), or stage IB and II (5-y RFS 36% vs 69%, p = 0.001). High expression of MCM4 correlated with other poor prognosis factors including smoking (p = 0.001), stage (p = 0.003), lymphovascular invasion (p = 0.036), visceral pleural invasion (p = 0.005), tumor necrosis (p < 0.0001) and solid histology (p < 0.0001). Conclusions: High MCM4 expression serves as an important prognostic biomarker predicting recurrence in early-stage node-negative lung adenocarcinoma.

scholarly journals Efficacy of the Management of Node Negative Early Stage Breast Cancer Using 1% Methylene Blue in Sentinel Lymph Node Biopsy:prospective study, kasrAlaini University Hospital

2021 ◽  
Vol 64 (12) ◽  
pp. 2-3
Author(s):  
Emad Khallaf ◽  
hasan Abouelnaga ◽  
Salma Dowara ◽  
Mohammed Daoud ◽  
Wael Lolah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Methylene Blue ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
University Hospital ◽  
Node Negative

CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma

2005 ◽  
Vol 11 (9) ◽  
pp. 3309-3314 ◽  
Author(s):  
Leslie K. Diaz ◽  
Xiao Zhou ◽  
Edward T. Wright ◽  
Massimo Cristofanilli ◽  
Terry Smith ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Invasive Breast Carcinoma ◽  
Node Negative ◽  
Cd44 Expression
Sign in / Sign up

Export Citation Format

Share Document